Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 7.54
PRTA's Cash-to-Debt is ranked lower than
59% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. PRTA: 7.54 )
Ranked among companies with meaningful Cash-to-Debt only.
PRTA' s Cash-to-Debt Range Over the Past 10 Years
Min: 7.54  Med: No Debt Max: No Debt
Current: 7.54
Equity-to-Asset 0.79
PRTA's Equity-to-Asset is ranked higher than
67% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. PRTA: 0.79 )
Ranked among companies with meaningful Equity-to-Asset only.
PRTA' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.78  Med: 0.94 Max: 0.98
Current: 0.79
-1.78
0.98
Piotroski F-Score: 1
Altman Z-Score: 11.76
Beneish M-Score: -3.76
WACC vs ROIC
26.70%
-1196.54%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -15121.80
PRTA's Operating Margin % is ranked lower than
94% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. PRTA: -15121.80 )
Ranked among companies with meaningful Operating Margin % only.
PRTA' s Operating Margin % Range Over the Past 10 Years
Min: -15121.8  Med: -4974.3 Max: -13.07
Current: -15121.8
-15121.8
-13.07
Net Margin % -15176.11
PRTA's Net Margin % is ranked lower than
94% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. PRTA: -15176.11 )
Ranked among companies with meaningful Net Margin % only.
PRTA' s Net Margin % Range Over the Past 10 Years
Min: -15176.11  Med: -5016.3 Max: -14.06
Current: -15176.11
-15176.11
-14.06
ROE % -39.56
PRTA's ROE % is ranked higher than
50% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. PRTA: -39.56 )
Ranked among companies with meaningful ROE % only.
PRTA' s ROE % Range Over the Past 10 Years
Min: -68.99  Med: -27.35 Max: -3.09
Current: -39.56
-68.99
-3.09
ROA % -34.53
PRTA's ROA % is ranked lower than
51% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. PRTA: -34.53 )
Ranked among companies with meaningful ROA % only.
PRTA' s ROA % Range Over the Past 10 Years
Min: -1640.13  Med: -32.1 Max: -2.94
Current: -34.53
-1640.13
-2.94
ROC (Joel Greenblatt) % -505.41
PRTA's ROC (Joel Greenblatt) % is ranked higher than
50% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. PRTA: -505.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PRTA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2303.58  Med: -1285.66 Max: -204.81
Current: -505.41
-2303.58
-204.81
3-Year Revenue Growth Rate -4.90
PRTA's 3-Year Revenue Growth Rate is ranked lower than
62% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. PRTA: -4.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PRTA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -33.7  Med: -15.05 Max: 289
Current: -4.9
-33.7
289
3-Year EBITDA Growth Rate 28.90
PRTA's 3-Year EBITDA Growth Rate is ranked higher than
81% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. PRTA: 28.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PRTA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -50.7  Med: 13.25 Max: 37.3
Current: 28.9
-50.7
37.3
3-Year EPS without NRI Growth Rate 28.40
PRTA's 3-Year EPS without NRI Growth Rate is ranked higher than
82% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. PRTA: 28.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PRTA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -47.9  Med: 13.1 Max: 36.8
Current: 28.4
-47.9
36.8
GuruFocus has detected 4 Warning Signs with Prothena Corp PLC $PRTA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PRTA's 10-Y Financials

Financials (Next Earnings Date: 2017-05-14 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PRTA Guru Trades in Q1 2016

Vanguard Health Care Fund 2,150,294 sh (+29.32%)
Ken Fisher 19,076 sh (+0.19%)
Jim Simons Sold Out
» More
Q2 2016

PRTA Guru Trades in Q2 2016

Pioneer Investments 119,958 sh (New)
Vanguard Health Care Fund 2,150,294 sh (unchged)
Ken Fisher 19,040 sh (-0.19%)
» More
Q3 2016

PRTA Guru Trades in Q3 2016

Vanguard Health Care Fund 2,150,294 sh (unchged)
Pioneer Investments 119,324 sh (-0.53%)
Ken Fisher 13,856 sh (-27.23%)
» More
Q4 2016

PRTA Guru Trades in Q4 2016

Vanguard Health Care Fund 2,150,294 sh (unchged)
Pioneer Investments 116,424 sh (-2.43%)
Ken Fisher 10,718 sh (-22.65%)
» More
» Details

Insider Trades

Latest Guru Trades with PRTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BCRX, NAS:ANIP, NAS:BSTC, AMEX:BTX, NAS:CASC, NAS:BDSI, NAS:BMRN » details
Traded in other countries:0PT.Germany,
Prothena Corp PLC is a biotechnology company. It discovers and develops novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion.

Prothena Corporation PLC was incorporated in Ireland as a private limited company under the name Neotope Corporation Limited on September 26, 2012. On November1, 2012, it changed the name of the company to Prothena Corporation plc. It is a biotechnology company engaged in the discovery and development of novel antibodies for the potential treatment of an array of diseases that involve protein misfolding or cell adhesion. Its research and development pipeline includes three main therapeutic antibody programs: NEOD001 for the treatment of AL and AA Amyloidosis; PRX002 (formerly NEOD002) for the treatment of Parkinson's disease; and PRX003 for the potential treatment of inflammatory disease and metastatic cancers. Its pipeline also includes two late discovery stage programs: tau antibodies for potential treatment of Alzheimer's disease and antibodies for the potential treatment of type 2 diabetes. The competitors consist of major international companies, all of which are larger and have greater financial resources, technical staff, manufacturing, R&D and marketing capabilities. It also competes with smaller research companies and generic drug and biosimilar manufacturers. It is subject to significant regulation by international, national, state and local governmental regulatory agencies.

Ratios

vs
industry
vs
history
PB Ratio 5.06
PRTA's PB Ratio is ranked lower than
61% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. PRTA: 5.06 )
Ranked among companies with meaningful PB Ratio only.
PRTA' s PB Ratio Range Over the Past 10 Years
Min: 0.84  Med: 3.43 Max: 6.28
Current: 5.06
0.84
6.28
PS Ratio 1726.64
PRTA's PS Ratio is ranked lower than
97% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. PRTA: 1726.64 )
Ranked among companies with meaningful PS Ratio only.
PRTA' s PS Ratio Range Over the Past 10 Years
Min: 8.25  Med: 308.46 Max: 1805.66
Current: 1726.64
8.25
1805.66
Current Ratio 9.53
PRTA's Current Ratio is ranked higher than
78% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. PRTA: 9.53 )
Ranked among companies with meaningful Current Ratio only.
PRTA' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 20.53 Max: 72.16
Current: 9.53
0.01
72.16
Quick Ratio 9.53
PRTA's Quick Ratio is ranked higher than
79% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. PRTA: 9.53 )
Ranked among companies with meaningful Quick Ratio only.
PRTA' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 20.53 Max: 72.16
Current: 9.53
0.01
72.16
Days Sales Outstanding 61.58
PRTA's Days Sales Outstanding is ranked lower than
52% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. PRTA: 61.58 )
Ranked among companies with meaningful Days Sales Outstanding only.
PRTA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.41  Med: 31.32 Max: 115.61
Current: 61.58
12.41
115.61

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -16.40
PRTA's 3-Year Average Share Buyback Ratio is ranked lower than
64% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. PRTA: -16.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PRTA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.6  Med: -18.95 Max: -14.7
Current: -16.4
-23.6
-14.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 6.30
PRTA's Price-to-Net-Cash is ranked higher than
52% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 6.36 vs. PRTA: 6.30 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PRTA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.06  Med: 3.46 Max: 6.58
Current: 6.3
1.06
6.58
Price-to-Net-Current-Asset-Value 6.21
PRTA's Price-to-Net-Current-Asset-Value is ranked lower than
51% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 5.79 vs. PRTA: 6.21 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PRTA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.05  Med: 3.43 Max: 6.48
Current: 6.21
1.05
6.48
Price-to-Tangible-Book 5.04
PRTA's Price-to-Tangible-Book is ranked lower than
54% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. PRTA: 5.04 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PRTA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.02  Med: 3.35 Max: 5.99
Current: 5.04
1.02
5.99
Price-to-Median-PS-Value 5.59
PRTA's Price-to-Median-PS-Value is ranked lower than
92% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. PRTA: 5.59 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PRTA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.03  Med: 2.26 Max: 5.83
Current: 5.59
0.03
5.83
Earnings Yield (Greenblatt) % -9.62
PRTA's Earnings Yield (Greenblatt) % is ranked lower than
54% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. PRTA: -9.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PRTA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -10.25  Med: 155.6 Max: 74709.2
Current: -9.62
-10.25
74709.2

More Statistics

Revenue (TTM) (Mil) $1.06
EPS (TTM) $ -4.66
Beta3.49
Short Percentage of Float18.31%
52-Week Range $33.53 - 68.18
Shares Outstanding (Mil)37.19

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 21 53 36
EPS ($) -3.12 -2.07 -4.77
EPS without NRI ($) -3.12 -2.07 -4.77
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PRTA

Headlines

Articles On GuruFocus.com
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
Prothena (PRTA) Potential Parkinson's Treatment, Envivio (ENVI) Improved Results, Nike (NKE) Profita Mar 20 2015 
Three Stocks With Massive Insider Buying Sep 03 2014 

More From Other Websites
Prothena Corp. Plc breached its 50 day moving average in a Bullish Manner : PRTA-US : March 27, 2017 Mar 27 2017
Don't Let Offerings Blindside Your Thesis Mar 19 2017
Why Is Prothena (PRTA) Up 4.5% Since the Last Earnings Report? Mar 17 2017
Results for Prothena's Phase 1b Multiple Ascending Dose Study of PRX002... Mar 09 2017
Results for Prothena’s Phase 1b Multiple Ascending Dose Study of PRX002/RG7935 in Patients with... Mar 09 2017
PROTHENA CORP PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 08 2017
Prothena Raises $155.3M to Bring Anti-Organ Failure Drug to Market Mar 03 2017
Prothena Announces Pricing of Public Offering of 2,700,000 Ordinary Shares Mar 03 2017
Prothena Announces Pricing of Public Offering of 2,700,000 Ordinary Shares Mar 03 2017
Prothena Corporation plc : Prothena Announces Public Offering of Ordinary Shares Mar 02 2017
Prothena Announces Public Offering of Ordinary Shares Mar 02 2017
PROTHENA CORP PLC Financials Mar 02 2017
Coverage initiated on Prothena by Instinet Mar 02 2017
PROTHENA CORP PLC Files SEC form 10-K, Annual Report Feb 27 2017
Prothena Corp. Plc :PRTA-US: Earnings Analysis: 2016 By the Numbers : February 17, 2017 Feb 17 2017
Prothena Corp. Plc :PRTA-US: Earnings Analysis: Q4, 2016 By the Numbers : February 16, 2017 Feb 16 2017
Prothena (PRTA) Reports Wider-than-Expected Loss in Q4 Feb 15 2017
Edited Transcript of PRTA earnings conference call or presentation 14-Feb-17 9:30pm GMT Feb 15 2017
Prothena reports 4Q loss Feb 14 2017
Prothena reports 4Q loss Feb 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)